Necrostatin-1 reduces intestinal inflammation and colitis-associated tumorigenesis in mice

American Journal of Cancer Research

Volumn 5, Issue 10, 2015, Pages 3174-3185

  Liu, Zhen Yu ^a   Wu, Bo ^a   Guo, Yun Shan ^a   Zhou, Ying Hui ^a   Fu, Zhi Guang ^a   Xu, Bao Qing ^a   Li, Jiang Hua ^a   Jing, Lin ^a   Jiang, Jian Li ^a   Tang, Juan ^a   Chen, Zhi Nan ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Colon cancer; Inflammatory bowel diseases; Murine colitis models; Necroptosis; Necrostatin 1

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; CASPASE 8; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 6; MEMBRANE PROTEIN; MIXED LINEAGE KINASE; MIXED LINEAGE KINASE DOMAIN LIKE PROTEIN; NECROSTATIN 1; RECEPTOR INTERACTING PROTEIN 1; RECEPTOR INTERACTING PROTEIN 3; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; COLITIS; COLITIS ASSOCIATED CANCER; COLON CANCER; COLON SHORTENING; COLONIC MUCOSA DAMAGE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; ENTERITIS; EX VIVO STUDY; FEMALE; HT 29 CELL LINE; MOLECULAR DYNAMICS; MOUSE; MUCOSAL DISEASE; NECROPTOSIS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; SYMPTOM; TUMOR VOLUME; UPREGULATION; WEIGHT REDUCTION;

EID: 85006226151     PISSN: None     EISSN: 21566976     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Rao VP, Poutahidis T, Ge Z, Nambiar PR, Boussahmain C, Wang YY, Horwitz BH, Fox JG and Erdman SE. Innate immune inflammatory response against enteric bacteria Helicobacter hepaticus induces mammary adenocarcinoma in mice. Cancer Res 2006; 66: 7395-7400.
2. Sin DD, Man SF, McWilliams A and Lam S. Progression of airway dysplasia and C-reactive protein in smokers at high risk of lung cancer. Am J Respir Crit Care Med 2006; 173: 535-539.
3. Gunter MJ, Stolzenberg-Solomon R, Cross AJ, Leitzmann MF, Weinstein S, Wood RJ, Virtamo J, Taylor PR, Albanes D and Sinha R. A prospective study of serum C-reactive protein and colorectal cancer risk in men. Cancer Res 2006; 66: 2483-2487.
4. Siegel R, Ma J, Zou Z and Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29.
5. Itzkowitz SH and Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 2004; 287: G7-17.
6. Ullman TA and Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology 2011; 140: 1807-1816.
7. Saleh M and Trinchieri G. Innate immune mechanisms of colitis and colitis-associated colorectal cancer. Nat Rev Immunol 2011; 11: 9-20.
8. Tait SWG and Green DR. Caspase-independent cell death: leaving the set without the final cut. Oncogene 2008; 27: 6452-6461.
9. Galluzzi L and Kroemer G. Necroptosis: a specialized pathway of programmed necrosis. Cell 2008; 135: 1161-1163.
10. Hitomi J, Christofferson DE, Ng A, Yao J, Degterev A, Xavier RJ and Yuan J. Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway. Cell 2008; 135: 1311-1323.
11. Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH, Blagosklonny MV, El-Deiry WS, Golstein P, Green DR, Hengartner M, Knight RA, Kumar S, Lipton SA, Malorni W, Nuñez G, Peter ME, Tschopp J, Yuan J, Piacentini M, Zhivotovsky B, Melino G; Nomenclature Committee on Cell Death 2009. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ 2009; 16: 3-11.
12. Pasparakis M and Vandenabeele P. Necroptosis and its role in inflammation. Nature 2015; 517: 311-320.
13. Gunther C, Martini E, Wittkopf N, Amann K, Weigmann B, Neumann H, Waldner MJ, Hedrick SM, Tenzer S, Neurath MF and Becker C. Caspase-8 regulates TNF-alpha-induced epithelial necroptosis and terminal ileitis. Nature 2011; 477: 335-339.
14. Welz PS, Wullaert A, Vlantis K, Kondylis V, Fernandez- Majada V, Ermolaeva M, Kirsch P, Sterner-Kock A, van Loo G and Pasparakis M. FADD prevents RIP3-mediated epithelial cell necrosis and chronic intestinal inflammation. Nature 2011; 477: 330-334.
15. Pierdomenico M, Negroni A, Stronati L, Vitali R, Prete E, Bertin J, Gough PJ, Aloi M and Cucchiara S. Necroptosis Is Active in Children With Inflammatory Bowel Disease and Contributes to Heighten Intestinal Inflammation. Am J Gastroenterol 2014; 109: 279-287.
16. Moquin D and Chan FK. The molecular regulation of programmed necrotic cell injury. Trends Biochem Sci 2010; 35: 434-441.
17. Christofferson DE and Yuan J. Necroptosis as an alternative form of programmed cell death. Curr Opin Cell Biol 2010; 22: 263-268.
18. Zhang DW, Shao J, Lin J, Zhang N, Lu BJ, Lin SC, Dong MQ and Han J. RIP3, an Energy Metabolism Regulator That Switches TNF-Induced Cell Death from Apoptosis to Necrosis. Science 2009; 325: 332-336.
19. Vandenabeele P, Declercq W, Van Herreweghe F and Vanden Berghe T. The role of the kinases RIP1 and RIP3 in TNF-induced necrosis. Sci Signal 2010; 3: re4.
20. Dong K, Zhu H, Song Z, Gong Y, Wang F, Wang W, Zheng Z, Yu Z, Gu Q, Xu X and Sun X. Necrostatin- 1 protects photoreceptors from cell death and improves functional outcome after experimental retinal detachment. Am J Pathol 2012; 181: 1634-1641.
21. King MD, Whitaker-Lea WA, Campbell JM, Alleyne CH Jr and Dhandapani KM. Necrostatin-1 reduces neurovascular injury after intracerebral hemorrhage. Int J Cell Biol 2014; 2014: 495817.
22. Wang Y, Wang J, Yang H, Zhou J, Feng X, Wang H and Tao Y. Necrostatin-1 mitigates mitochondrial dysfunction post-spinal cord injury. Neuroscience 2015; 289: 224-232.
23. Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, Scheller J, Rose-John S, Cheroutre H, Eckmann L and Karin M. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009; 15: 103-113.
24. Siegmund B, Lehr HA, Fantuzzi G and Dinarello CA. IL-1 beta -converting enzyme (caspase-1) in intestinal inflammation. Proc Natl Acad Sci U S A 2001; 98: 13249-13254.
25. Siegmund B, Lehr HA and Fantuzzi G. Leptin: a pivotal mediator of intestinal inflammation in mice. Gastroenterology 2002; 122: 2011-2025.
26. Sun L, Wang H, Wang Z, He S, Chen S, Liao D, Wang L, Yan J, Liu W, Lei X and Wang X. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell 2012; 148: 213-227.
27. He S, Wang L, Miao L, Wang T, Du F, Zhao L and Wang X. Receptor interacting rotein kinase-3 determines cellular necrotic response to TNFalpha. Cell 2009; 137: 100-1111.
28. Wang H, Sun L, Su L, Rizo J, Liu L, Wang LF, Wang FS and Wang X. Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon hosphorylation by RIP3. Mol Cell 2014; 54: 133-146.
29. Kaczmarek A, Vandenabeele P and Krysko DV. Necroptosis: the release of damage-associated molecular patterns and its physiological relevance.Immunity 2013; 38: 209-223.
30. Harris HE, Andersson U and Pisetsky DS. HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol 2012; 8: 195-202.
31. Assi K, Pillai R, Gomez-Munoz A, Owen D and Salh B. The specific JNK inhibitor SP600125 targets tumour necrosis factor-alpha produc tion and epithelial cell apoptosis in acute murine colitis. Immunology 2006; 118: 112-121.
32. Sancho R, Nateri AS, de Vinuesa AG, Aguilera C, Nye E, Spencer-Dene B and Behrens A. JNK signalling modulates intestinal homeostasis and tumourigenesis in mice. EMBO J 2009; 28: 1843-1854.
33. Siegmund B, Rieder F, Albrich S, Wolf K, Bidlingmaier C, Firestein GS, Boyle D, Lehr HA, Loher F, Hartmann G, Endres S and Eigler A. Adenosine kinase inhibitor GP515 improves experimental colitis in mice. J Pharmacol Exp Ther 2001; 296: 99-105.
34. Cai Z, Jitkaew S, Zhao J, Chiang HC, Choksi S, Liu J, Ward Y, Wu LG and Liu ZG. Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis. Nat Cell Biol 2014; 16: 55-65.
35. Eaden JA, Abrams KR and Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48: 526-535.
36. Balkwill F and Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357:539-545.
37. Cooper HS, Murthy S, Kido K, Yoshitake H and Flanigan A. Dysplasia and cancer in the dextran sulfate sodium mouse colitis model. Relevance to colitis-associated neoplasia in the human: a study of histopathology, B-catenin and p53 expression and the role of inflammation. Carcinogenesis 2000; 21: 757-768.
38. Suzuki R, Kohno H, Sugie S, Nakagama H and Tanaka T. Strain differences in the susceptibility to azoxymethane and dextran sodium sulfate- induced colon carcinogenesis in mice.Carcinogenesis 2006; 27: 162-169.
39. Kim S, Keku TO, Martin C, Galanko J, Woosley JT, Schroeder JC, Satia JA, Halabi S and Sandler RS. Circulating levels of inflammatory cytokines and risk of colorectal adenomas. Cancer Res 2008; 68: 323-328.
40. Gautheron J, Vucur M, Reisinger F, Cardenas DV, Roderburg C, Koppe C, Kreggenwinkel K, Schneider AT, Bartneck M, Neumann UP, Canbay A, Reeves HL, Luedde M, Tacke F, Trautwein C, Heikenwalder M and Luedde T. A positive feedback loop between RIP3 and JNK controls non-alcoholic steatohepatitis. EMBO Mol Med 2014; 6: 1062-1074.
41. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000; 103: 239-252.